Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors

NCT06026410 is registered in ClinicalTrials.gov with Kura Oncology, Inc. as lead sponsor.

NCT NCT06026410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06026410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors
Lead sponsor
Kura Oncology, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
October 18, 2023
Completion date
April 30, 2027
Enrollment
300 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma (ccrcc), colorectal cancer (crc), non clear cell renal cell carcinoma (nccrcc), non small cell lung cancer (nsclc), pancreatic ductal adenocarcinoma (pdac), renal cell carcinoma (kidney cancer), solid tumors with hras alterations